Linked Life Data

12624803

Source:http://linkedlifedata.com/resource/pubmed/id/12624803

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-3-7
pubmed:abstractText
As described elsewhere the oral administration of 5 mg of the 5-HT3-receptor-antagonist Tropisetron in fibromyalgia exhibited less amelioration of pain in patients with a depression in comparison to patients without depression. Since an intravenous treatment seems to increase the effect of Tropisetron, the question arises whether patients with depression profit from the intravenous therapy. Methods 68 out patients with fibromyalgia according to ACR-criteria were enrolled in the study. The patients filled in a VAS pain and the Beck Depression Inventory (BDI) before and after a bolus i.v. injection of 5 mg Tropisetron for 5 days [Beck AT, Steer Ra. Beck-Depression-Inventory (BDI) In: Hautzinger M (Hrsg der dt. Ausg.). Testhandbuch. 1. Auflage Bern: Verlag Hans Huber, 1994]. In the beginning the patients had to have > or = 40 mm in the VAS pain from 0-100 mm. The patients were divided into three groups: group 1 = patients with a BDI<19 without experience with antidepressive drugs (n=26); group 2=patients with a BDI > or = 19 (n=22) and negative experience with antidepressive substances, and group 3=patients with a BDI > or = 19 and an accompanying antidepressant drug therapy and some benefit under this therapy (n=20). Results Before the therapy there was no significant difference in VAS pain in the groups, but in BDI there was a significant difference between group 1 (BDI mean value 11.5) in comparison to group 2 (BDI mean value 26.1) and group 3 (BDI mean value 24.8). After therapy all three groups had a significant amelioration of pain: group 1: p=0.000023; group 2: p=0.00073; group 3: p=0.0145. There was a significant difference between the group with BDI<19 and the group with antidepressant drug in amelioration of pain (p=0.044). A significant correlation was found in group 2 with Beck > or = 19 between amelioration of pain and BDI after therapy (p=0.008, r=0.666). In this group a pain-reactive depression and in group 3 an endogenous depression must be discussed.
pubmed:commentsCorrections
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0340-1855
pubmed:author
pubmed:issnType
Print
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
42-5
pubmed:dateRevised
2009-11-3
pubmed:meshHeading
pubmed-meshheading:12624803-Adjustment Disorders, pubmed-meshheading:12624803-Administration, Oral, pubmed-meshheading:12624803-Adult, pubmed-meshheading:12624803-Amitriptyline, pubmed-meshheading:12624803-Depressive Disorder, pubmed-meshheading:12624803-Drug Therapy, Combination, pubmed-meshheading:12624803-Female, pubmed-meshheading:12624803-Fibromyalgia, pubmed-meshheading:12624803-Fluoxetine, pubmed-meshheading:12624803-Humans, pubmed-meshheading:12624803-Indoles, pubmed-meshheading:12624803-Injections, Intravenous, pubmed-meshheading:12624803-Middle Aged, pubmed-meshheading:12624803-Pain Measurement, pubmed-meshheading:12624803-Personality Inventory, pubmed-meshheading:12624803-Receptors, Serotonin, pubmed-meshheading:12624803-Receptors, Serotonin, 5-HT3, pubmed-meshheading:12624803-Serotonin Antagonists, pubmed-meshheading:12624803-Sick Role, pubmed-meshheading:12624803-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
[The influence of depression on the effect of Tropisetron in the therapy of fibromyalgia].
pubmed:affiliation
Hochrhein-Institut für Rehabilitationsforschung, Rheumaklinik, Bergseestr. 61, 79713 Bad Säckingen, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, English Abstract